Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma

Guillermo De Velasco, Wanling Xie, Frede Donskov, Laurence Albiges, Benoit Beuselinck, Sandy Srinivas, Neeraj Agarwal, Jae Lyun Lee, James Brugarolas, Lori A. Wood, Sun young Rha, Christian Kollmannsberger, Scott North, Ravindran Kanesvaran, Brian I. Rini, Reuben Broom, Haru Yamamoto, Marina D. Kaymakcalan, Daniel Y.C. Heng, Toni K. Choueiri